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ABSTRACT 
Objective: The aim of the present work was to develop a simple, rapid, accurate and economical UV-visible spectrophotometric method for the 
determination of hydroquinone (HQ) in its pure form, marketed formulation as well as in the prepared nanostructured lipid carrier (NLC) systems 
and to validate the developed method. 
Methods: HQ was estimated at UV maxima of 289.6 nm in pH 5.5 phosphate buffer using UV-Visible double beam spectrophotometer. Following the 
guidelines of the International Conference on Harmonization (ICH), the method was validated for various analytical parameters like linearity, 
precision, and accuracy robustness, ruggedness, limit of detection, quantification limit, and formulation analysis. 
Results: The obtained results of the analysis were validated statistically. Recovery studies were performed to confirm the accuracy of the proposed 
method. In the developed method, linearity over the concentration range of 5-40 μg/ml of HQ was observed with the correlation coefficient of 0.998 
and found in good agreement with Beer Lambert’s law. The precision (intra-day and inter-day) of the method was found within official RCD limits 
(RSD<2%).  
Conclusion: The sensitivity of the method was assessed by determining the limit of detection and limit of quantification. It could be concluded from 
the results obtained that the purposed method for estimation of HQ in pure form, in the marketed ointment and in the prepared NLC-formulation 
was simple, rapid, accurate, precise and economical. It can be used successfully in the quality control of pharmaceutical formulations and for the 
routine laboratory analysis. 
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Hydroquinone is chemically (1, 4-dihydroxybenzene) phenolic 
compound (fig. 1) having chemical formula C6H4 (OH)2. It is a water-
soluble reducing agent which is used widely in topical skin creams. 
It acts as a di-pigmenting agent by inhibiting melanogenesis [1, 2]. It 
is useful in the treatment of dyschromias (melasma), contact vitiligo, 
post inflammatory hyper pigmentation (PIH), seborrheic dermatitis 
and exogenous ochronosisetc [3]. 
 
 
Fig. 1: Chemical structure of hydroquinone 
 
HQ mainly affects melanocytes in the process of melanogenesis and 
treated as the gold standard therapy for PIH. It acts by causing 
reversible inhibition of tyrosinase enzymes and damage 
melanosomes and melanocytes, thus it lowers down the melanin 
content in the new keratinocytes formed. It is commonly used at 
concentrations of 2-4% [4]. It is safely combined with retinoids and 
steroids in kligman’s regimen (5% hydroquinone, 0.1% 
dexamethasone, 0.1% tretinoin) used to treat hyper pigmentation. 
The commercially available HQ cream 4% is a whitish cream and is 
indicated for acute hyperpigmentation resulting due to acne scars, 
PIH, melasma, etc. HQ, when used in concentrations greater than 
4%, can lead to skin irritation, skin redness, and dermatitis, etc.[5]. 
Topical drugs, when delivered through conventional formulations, 
faces the major hurdle of crossing the stratum corneum layer which 
act as a barrier against skin permeation. So, these drugs are 
formulated in lipid carrier systems like liposomes, niosomes, solid 
lipid nanoparticles (SLN), nano lipid carriers (NLC), ethosomes, 
transferosomes which increase skin permeation and further 
improves the bioavailability of active molecule [6-9]. In the present 
study, NLC formulation of HQ was prepared that provides effective 
treatment in hyper pigmentation and melasma by passing the major 
obstacle in skin permeation. A detailed literature survey regarding 
existing methods of analysis like high-performance liquid 
chromatography (HPLC) [10], thin layer chromatography (TLC) [11], 
micellar electrokinetic chromatography (MEKC) [12], and capillary 
electrochromatography (CEC) techniques [13] in various biological 
matrices revealed that these methods are expensive, more 
sophisticated and involves extensive skills, thus there is need to 
develop simple spectrophotometric method for the estimation of 
Hydroquinone in various dosage forms. There is one reported UV 
spectrophotometric method for the estimation of hydroquinone 
individually in liposomes using methanol [14] and other UV 
spectrophotometric method for the simultaneous estimation of 
tazarotene and hydroquinone in gel preparation [15]. The present 
study focus on the development of more suitable, cheap, easy and 
validated UV spectrophotometric method for determination of HQ in 
different dosage forms that eliminate the use of toxic organic 
solvents and provides the eco-friendly study. In this context, UV-
spectrophotometry is the best-reported method. So the principle 
objective of the study was to develop UV spectrophotometric 
method with good linear range and sensitivity for the assay of 
hydroquinone in the marketed cream and NLC. 
MATERIALS AND METHODS 
Material 
A standard sample of HQ was obtained as a gratis sample from 
Chemitt India Pvt. Ltd. The marketed hydroquinone cream USP 
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containing 4% w/w of hydroquinone manufactured by Abbott 
Healthcare Pvt. Ltd, was procured from local market. 
For preparation of HQ loaded NLC  
Compritol 888 ATO and TPGS 1000 was obtained as gift sample from 
Stearinerie Dubois Fils, Ciron, France and Isochem S. A. 
Gennevilliers, France respectively. Pure almond oil was gifted by 
Yash Exports. Transcutol was obtained from CDH laboratories. All 
the other chemicals used in the study were of analytical grades. 
Instrumentation 
For method validation 
A double beam Systronics UV-Visible spectrophotometer, model UV-
2201 (India) with a spectral bandwidth of 1 nm, wavelength 
accuracy of±0.5 nm and a pair of 1 cm quartz cells were used to 
measure the absorbance of the resulting solutions. 
For the preparation of NLC of HQ 
Homogenizer, RQT-127A remimotors, Vasai, India, magnetic 
stirrer LE-17 spruce enterprises, Ambala (Haryana), bath 
sonicator, Apl Indian Machine tools, Delhi were used to prepare 
NLC of HQ 
Preparation of hydroquinone-loaded NLC 
An accurately weighed 100 mg of drug was added in a molten 
solution of solid lipid (compritol 888 ATO) and liquid lipid (almond 
oil) at the melting temperature (72 °C) of solid lipid. The surfactant 
solution was prepared separately by adding TPGS 1000 to the 50 ml 
of the distilled water containing transcutol as co-surfactant at bath 
sonicator for about 15 min which was later heated to the same 
temperature as melted lipid. A weighed amount of drug was 
dissolved in the 10 ml of heated surfactant solution and added drop-
wise to the lipid melt under constant temperature and stirring 
conditions. Further, the entire surfactant solution was added and 
stirred continuously for about half hour. The mixture was then 
transferred into high shear homogenizer and stirred for about 20 
min at the speed of 12,000 rpm. The final formulation was collected 
and cooled down in the beaker [16, 17]. 
Analytical method development 
Selection of solvent 
A suitable solvent is selected on the basis of stability and 
solubility of the drug in solvent system as well as extraction of 
the drug from its formulation [18]. HQ pure form, HQ NLC 
formulation and its marketed formulation can freely solubilize in 
5.5 pH phosphate buffer which also resembles to the pH of the 
skin.  
Hence 5.5 pH phosphate buffer was selected as a solvent for UV 
spectrophotometric determination. 
Preparation of standard stock solution (1000μg/ml) 
Accurately weighed quantity of 100 mg of HQ was transferred into 
100 ml volumetric flask which was dissolved and diluted up to the 
mark with 5.5 pH phosphate buffer [19]. The solution was sonicated 
on bath sonicator to get a clear standard stock solution 
(1000μg/ml). 
Determination of λ max 
The standard stock solution of HQ having the concentration 
1000μg/ml was further diluted to 100μg/ml with 5.5 pH 
phosphate buffer. The absorbance of the resultant solution was 
scanned in the UV spectrophotometer ranging from 200-400 nm 
[20, 21]. The plot shows the maximum absorbance at 289.6 nm as 
shown below in fig. 2. 
 
 
Fig. 2: UV visible spectrum scan of HQ showing λ maxat 289.6 nm 
 
Preparation of standard sample solution (pure drug) 
For the spectrophotometric analysis, stock solution of HQ was 
prepared by dissolving 100 mg of HQ in 100 ml of 5.5 pH phosphate 
buffer to obtain a final concentration of 1000 μg/ml. Further, the 
mixture was sonicated for 1 minute. The solution was then filtered 
[22, 23]. From this stock solution, 10 ml of the solution was taken 
and transferred to 100 ml volumetric flask and diluted with 5.5 pH 
phosphate buffer to get the solution with concentration of100μg/ml. 
From this solution, serial dilutions were made to prepare sample 
solutions of concentrations ranging from 5-40 μg/ml and were 
analyzed at 289.6 nm. 
Preparation of test sample solution (Marketed formulation) 
An amount equivalent to 100 mg of HQ from commercially 
available, MELALITE® FORTE CREAM 4% USP (ABBOTT 
HEALTHCARE) was weighed accurately and transferred into 100 
ml volumetric flask. 20 ml of 5.5 pH phosphate buffer was added 
and mixed thoroughly and the volume was made up to 100 ml 
with the same solvent, the mixture was then sonicated for 1 
minute and filtered through whatmann filter paper (no. 41). 
From this stock solution, 10 ml of solution was taken and 
transferred to 100 ml volumetric flask and diluted with 5.5 pH 
phosphate buffer. From this solution, dilutions were prepared 
and analyzed at 289.6 nm. 
Preparation of test sample solution (Prepared NLC formulation) 
An accurate volume of an amount equivalent to 100 mg of HQ from 
prepared NLC formulation was taken accurately and mixed with 25 
ml of 5.5 pH phosphate buffer and volume was made up to 100 ml 
with buffer, the mixture was sonicated for 1 minute and finally 
filtered through Whatman filter paper (no. 41) [24]. From this stock 
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solution, 10 ml of solution was taken and transferred to 100 ml 
volumetric flask and diluted with 5.5 pH phosphate buffer to 100 ml. 
From this solution, various dilutions were prepared and analyzed at 
289.6 nm. 
Validation of UV spectrophotometric method 
Linearity and range 
From the stock solution, aliquots of concentrations ranging from 
5-40 μg/ml were prepared in triplicate. Absorbance values of 
these solutions were measured at λmax 289.6 nm. The 
calibration curve was plotted between concentrations of HQ and 
respectively measured absorbances. Linearity was calculated by 
least square regression method [25]. The stability of the drug in 
the solvent system and during the actual analysis was also 
investigated.  
Accuracy 
Accuracy and precision of the method were studied with the help of 
percent recovery, standard deviation (SD), and percent relative 
standard deviation (RSD) by using standard addition method. 
Accuracy is the percentage of analyte recovered by an assay from the 
known added amount. Three levels of standard drug (75%, 100%, and 
125%) from HQ sample solution were spiked individually with the 10 
μg/ml equivalent of HQ MELALITE ®forte cream 4% USP and 10 μg/ml 
equivalent concentration of HQ from prepared HQ loaded NLC 
formulation [26-27]. All the readings were taken in triplicate at all 
levels. 
Precision 
Precision is the degree of repeatability of an analytical method 
under normal operational conditions. The precision of the method 
was determined by repeatability (intraday) and intermediate 
precision (inter-day) and reported as RSD % for a statistically 
significant number of replicate measurements [28]. Samples at 
different concentrations were analyzed in three replicates during 
the same day (intraday precision) and three consecutive days (inter-
day precision). The results obtained were tabulated along with 
standard error and 95% confidence interval. 
Limit of detection (LOD) and limit of quantitation (LOQ) 
LOD represents the lowest amount of an analyte in a sample that an 
analytical process can differentiate from other levels. The LOD and 
LOQ were determined by using the standard deviation of the 
response and slope of the corresponding calibration curve. LOD was 
determined by using following equation 
LOD = 3.3 ∗  σ/s 
Where, σ = the standard deviation of y-intercepts of regression lines 
S = the slope of the calibration curve [29]. 
LOQ represents the lowest concentration of an analyte in a sample 
which can be quantitatively determined with an acceptable 
accuracy, precision and variability. LOQ was calculated by using the 
following relation 
LOQ = 10 ∗  σ/s 
Repeatability 
Repeatability was determined by analyzing 20 μg/ml 
concentration of HQ solution for six times. From the resulting 
absorbance, the standard deviation and relative standard 
deviation were calculated [30]. 
Ruggedness 
The ruggedness of the proposed method was determined for 20 
μg/ml concentration of HQ by analysis of aliquots from a 
homogenous slot by two analysts using same operational and 
environmental conditions [30]. 
Robustness 
Robustness was studied by evaluating the influence of small but 
deliberate variations in the experimental condition like changing 
the wavelength (287.6 and 291.6 nm) for the analytical 
performance [31]. 
Forced degradation study 
A 2 ml aliquot of standard stock solution of HQ (1 mg/ml) was 
taken in four replicates in a volumetric flask (100 ml) and mixed 
with10 ml of 0.1N HCl (acid hydrolysis) or 0.1N NaOH (alkaline 
hydrolysis) or 5% H2O2 (oxidative degradation) and set aside for 
1 h at room temperature.  
The solution was diluted up to mark with distilled water. For 
photolytic degradation, a solution of drug (20 g/ml) was 
prepared as per the procedure under construction of the 
calibration graph and was exposed to UV radiation of 
wavelength 289.6 nm and of 1.4 flux intensity for 24 h in a UV 
chamber. For thermal degradation solid drug was kept in an 
oven at 100∘C for 24h [32].  
After cooling to room temperature, 20 g/ml concentrated 
solution of drug was prepared by above said method. Finally, 
absorbance of all the solutions as the result of acidic and alkaline 
hydrolysis, oxidative, photolytic, and thermal degradation were 
measured at 289.6 nm against their solvent respectively as blank 
in each case [33]. 
RESULTS AND DISCUSSION 
Linearity and range 
It was found that the selected drug shows linearity between the 
range of 5-40μg/ml. Linearity range is presented in table 1. The 
regression coefficient was found to be 0.998, which meet the method 
validation, acceptance criteria and hence the method is said to be 
linear in the range of 5-40 μg/ml as shown below in fig. 3.  
The calibration curve shows that the drug obeys Beer’s law limit 
within the concentration range. Furthermore, the overlay spectra of 
HQ in 5.5 pH phosphate buffer support the linearity results observed 
in the standard curve as in fig. 3. 
 
Table 1: Calibration data of HQ by UV-spectroscopy 
S. No. Concentration (μg/ml) Absorbance*(nm) 
1. 5 0.086±0.003 
2. 10 0.197±0.021 
3. 15 0.318±0.002 
4. 20 0.428±0.004 
5. 25 0. 535±0.001 
6. 30 0.655±0.003 
7. 35 0.764±0.002 
8. 40 0.867±0.014 
 *Average of three determinations. 
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Fig. 3: Calibration curve of hydroquinone 
 
 
Fig. 4: Overlay spectra of HQ (λ max 289.6) with concentration range from5-25 μg/ml 
 
Accuracy of marketed and prepared NLC-formulation 
Solutions were prepared in triplicate at levels 75%, 100% and 125% 
of drug concentration to the pre-analyzed HQ standard samples and 
the percent recovery values were calculated. The recovery results 
showed that the proposed method has an acceptable level of 
accuracy for HQ (75%-125% of marketed formulation 
concentration) in the range of 99 %-100%. 
Commercially available cream of HQ MELALITE® forte cream 4% 
USP (ABBOTT HEALTHCARE) and the prepared NLC formulation 
were selected for the estimation of total content by the proposed 
method. The acceptable level of HQ in 75%-125% of test 
concentration of prepared NLC-formulation was from 96-98%. 
Thus, the study indicates the absence of interaction between the 
drug and pharmaceutical additives and excipients. The results 
for both are shown in table 2 and 3, respectively. The differences 
between the assays obtained from the nine determinations (3 
conc/3 replicates) are within the limits for both of marketed 
cream and prepared NLC. The % RSD acceptance criterion is 2%. 
 
Table 2: Results of recovery studies for marketed cream 
Recovery level Initial conc. (μg/ml) Conc. of standard drug added (μg/ml) Abs. Mean* % recovery±SD  
75% 10 5 0.108 99.69±0.48 
100% 10 10 0.217 100.77±0.32 
125% 10 15 0.323 99.69±0.12 
*Average of three concentration 
 
Table 3: Result of recovery analysis of HQ NLC-formulation 
Recovery level Conc. of drug from formulation (μg/ml) Conc. of standard drug added (μg/ml) Abs. mean* % recovery±SD 
75% 10 5 4.846 96.91±0.39 
100% 10 10 9.985 99.85±0.63 
125% 10 15 14.830 98.87±0.02 
*Average of three concentration 
 
Precision 
The intraday and interday precisions were calculated by observing 
absorbance at three different time points in a day and for the three 
consecutive days. The absorbance result mean, SD and % RSD was 
calculated and shown in table 5 and 6. 
The acceptable limit for intraday variation should be within 1% and 
for inter-day variation should be within 2%, and the results were 
found to be in range. Precision results thus indicate that the 
validation method used is reliable and repeatable. So, it can be 
successfully used for determination of drug in various different 
pharmaceutical dosage forms. 
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Table 5: Intra-day precision data and statistical results 
Concentration taken 
(μg/ml) 
Mean conc. found at 10 
a. m. 
Mean conc. found at 12 
a. m. 
Mean conc. found at 2 
p. m. 
Mean* SD* % RSD* 
10 9.167 9.120 9.167 9.151 0.02673 0.29208 
15 14.722 14.722 14.769 14.738 0.02673 0.18137 
20 19.815 19.861 19.722 19.799 0.07071 0.35718 
*Average of three concentrations 
 
Table 6: Inter-day precision data and statistical results 
Concentration taken 
(μg/ml) 
Mean conc. found on 
Day 1 
Mean conc. found on 
Day 2 
Mean conc. found on 
Day 3 
Mean* SD* % RSD* 
10 9.120 9.120 9.074 9.105 0.02673 0.29357 
15 14.676 14.722 14.629 14.675 0.04629 0.31546 
20 19.769 19.769 19.722 19.753 0.02673 0.135316 
*Average of three concentrations 
 
Repeatability 
The % RSD was found to be 0.24 as shown in table 7. The 
repeatability results of six determinations with same 
concentration are found to be within limits. Repeatability plays 
very crucial role in the analysis of drug in bulk as well as in 
formulations. The results obtained from the repeatability study 
proved that there was no significant change observed on 
repetition of methodology. The % RSD observed was 0.24 and the 
acceptance criterion is 2%. 
 
Table 7: Results showing repeatability studies 
S. No. Concentration taken (μg/ml) Conc. found (μg/ml) 
 1. 20 19.861 
 2. 20 19.769 
 3. 20 19.769 
 4. 20 19.861 
 5. 20 19.861 
 6. 20 19.861 
 Mean* 19.830 
 SD 0.04781 
 %RSD 0.24112 
*Average of six determinations 
 
Ruggedness 
The result was indicated as % RSD. The results of two analysts with 
HQ of same concentrations with 6 determinants was shown within 
limits and Acceptance criteria is 2%. This parameter helps in 
confirming that no significant change in reliability and repeatability 
of methodology was observed with the change of analyst. The % RSD 
was found to be 0.14 as shown in table 8. 
 
Table 8: Results indicating ruggedness study 
Concentration taken (μg/ml) Conc. found by analyst 1 (μg/ml) Conc. found by analyst 2 (μg/ml) 
20 19.861 21.329 
20 19.814 21.279 
20 19.814 21.378 
20 19.861 21.329 
20 19.861 21.329 
20 19.861 21.329 
Mean* 19.846 21.329 
SD 0.02391 0.03137 
% RSD 0.12047 0.14708 
*Average of six determinations 
 
Robustness 
The respective absorbances were noted and the result was 
indicated as % RSD. The results were obtained at two different 
wavelengths. Linearity in the results was obtained at specific 
wavelengths with % RSD was found to be almost similar. No 
significant variation was observed in the absorbance of samples. 
Therefore, the proposed method was considered as robust. The 
Acceptance Criteria is 2%, hence the results obtained were within 
the range. 
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Table 9: Results showing robustness study 
Concentration taken (μg/ml) Conc. found at 287.6 nm Conc. found at 291.6 nm 
20 20.556 18.287 
20 20.707 18.194 
20 20.601 18.241 
20 20.509 18.241 
20 20.509 18.241 
20 20.556 18.241 
Mean* 20.548 18.241 
SD 0.03485 0.02928 
% RSD 0.16961 0.16052 
*Average of six determinations 
 
Assay 
The assay for marketed as well as for HQ-loaded NLC formulation having 
concentration 10(μg/ml) is shown in table 4. The % age drug recovery 
was calculated from absorbance value. The validity of the current 
method was confirmed as validated as the % age drug recovery was 
observed to be 90.43% in case of marketed dosage form of HQ while it 
was observed to be 91.51% in prepared NLC formulation. 
Degradation studies 
The result of stability studies conducted under different degradation 
conditions. Percentage degradation was calculated by the formula as 
given below and percentage recovery was also calculated in each 
case as shown in table 10. 





Table 4: Assay of marketed and prepared NLC formulation of HQ 
Formulation Amount taken* (μg/ml) Amount recovered SD* % drug 
recovered*±SD 
% RSD* 
Melalite® Forte Cream 4% USP 10 9.043 0.00116 90.43±0.001 0.591144 
Hydroquinone-loaded NLC formulation 10 9.151 0.00058 91.51±0.001 0.292083 
*mean of three values 
 
Table 10: Table depicting degradation and stability studies 
Parameters studied Conc. taken (μg/ml) Conc. found (μg/ml) % degradation* % recovery* 
Acid Hydrolysis 20 14.769 26.16 73.84% 
Alkaline Hydrolysis 20 18.935 5.32 94.68% 
Oxidative degradation 20 13.796 31.02 68.98% 
UV degradation 20 19.814 0.93 99.07% 
Thermal degradation 20 19.861 0.69 99.31% 
*Average of three concentrations 
 
The results revealed no change in absorbance of drug solution on UV 
and thermal degradation as the% recovery is very close to 100% 
which indicates good stability while slight degradation was 
observed on alkaline hydrolysis. But there was significant change 
observed with the drug was subjected to acid hydrolysis and (% 
degradation of 26.16) and oxidative degradation (% degradation of 
31.02%) confirming that HQ is prone to oxidation as well as acid 
hydrolysis.
 
Table 11: Table indicating the linearity data of developed method 
Parameters  Values 

 max (nm) 289.6 
Linearity range (μg/ml) 5-40 
LOD(μg/ml) 0.3161 
LOQ(μg/ml) 0.9578 
Standard Regression Equation y = 0.0216x 
Slope (m) 0.0216 
Y-intercept (c) 0 
Correlation Co-efficient(R2) 0.998 
% RSD Intra-day(n=3) 14.56 
% RSD Inter-day(n=3) 14.5113 
% Recovery 100.05 
 
CONCLUSION 
HQ was subjected to various studies as per ICH guidelines. It was 
found that HQ undergoes significant degradation under acid 
hydrolysis and is highly prone to oxidation which generally due to 
its conversion to benzoquinone, whereas it is stable under alkaline 
UV and thermal treatment. The proposed method was validated for 
linearity, accuracy, precision, ruggedness and robustness. The 
method was also applied to marketed as well as prepared NLC 
formulation and results were statistically compared with reference 
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method which showed that there were no significant changes in the 
result. So, the method can be utilized for determination of the purity 
of drug available from various sources without any tedious 
procedure and also used in the analysis of stability study samples. 
ACKNOWLEDGMENT 
The authors are grateful to the Rayat Bahra Institute of Pharmacy, 
Hoshiarpur, India, for giving permission to carry out their research work. 
CONFLICT OF INTERESTS 
The authors declare that there is no conflict of interests regarding 
the publication of this paper. 
REFERENCES 
1. Jow, Tiffany J, Hantash, Basil M. Hydroquinone-induced 
depigmentation: case report and review of the literature. 
Dermatitis 2014;25:1-5. 
2. TseTW. Hydroquinone for skin lightening: safety profile, 
duration of use and when should we stop? J Dermatolog Treat 
2010;21:272-5. 
3. Yayli S. Treatment of hyperpigmentation in darker skins. J 
Pigment Disord 2015;1:158-9. 
4. Nordlund JJ. Hyperpigmentation: its historical treatment and the 
development of hydroquinone. J Pigment Disord 2015;2:221. 
5. Palumbo A, d'Ischia M, Misuraca G, Prota G. Mechanism of 
inhibition of melanogenesis by hydroquinone. Biochim Biophys 
Acta 1991;1073:85–90.  
6. Verma DD, Verma S, Blume G, Fahr A. Liposomes increase skin 
penetration of entrapped and non-entrapped hydrophilic 
substances into human skin: a skin penetration and confocal 
laser scanning microscopy study. Eur J Pharm Biopharm 
2003;55:271-7. 
7. Shatalebi MA, Mostafavi SA, Moghaddas A. Niosome as a drug 
carrier for topical delivery of N-acetyl glucosamine. Res Pharm 
Sci 2010;5:107-17. 
8. Schlupp P, Blaschke T, Kramer KD, Holtje HD. Drug release and 
skin penetration from solid lipid nanoparticles and a base 
cream: a systematic approach from a comparison of three 
glucocorticoids. Skin Pharmacol Physiol 2011;24:199-209. 
9. Babaei S, Ghanbarzadeh S, Adib ZM, Kouhsoltani M. Enhanced 
skin penetration of lidocaine through encapsulation into 
nanoliposomes and nanostructured lipid carriers: a 
comparative study. Pharmazie 2016;71:247-51. 
10. Jain N, Jain R, Banweer J. Development and validation of a rapid 
RP-HPLC method for the determination of amlodipine besylate 
and olmesartan medoxomil in their combined tablet 
formulation. Int J Curr Pharm Res 2010;2:40-3. 
11. Siddique S, Parveen Z, Ali Z, Zaheer M. Qualitative and 
quantitative estimation of hydroquinone in skin whitening 
cosmetics. J Cosmetis Dermatological Sci Appl 2012;2:224-8. 
12. Seokmin J, Yongseong K. Analysis of hydroquinone and its ether 
derivatives by using micellar electrokinetic chromatography 
(MEKC). Bull Korean Chem Soc 2005;26:819-22. 
13. Desiderio C, Ossicini L, Fanali S. Analysis of hydroquinone and 
some of its ethers by using capillary electrochromatography. J 
Chromatogr A 2000;887:489-96. 
14. Khoshneviszadeh R, Bazzaz BSF, Housaindokht MR, Ebrahim-
Habibi A, Rajabi O. UV spectrophotometric determination and 
validation of hydroquinone in liposome. Iranian J Pharm Res 
2015;14:473-8. 
15. Jogarami R, Jain P, Sharma S. Validated UV spectrophotometric 
method development for simultaneous estimation of 
tazarotene and hydroquinone in gel preparation. J Pharm Res 
2012;5:2273-5. 
16. Ghanbarzadeh S, Hariri R, Kouhsoltani M, Shokri J, Javadzadeh 
Y, Hamishehkar H. Enhanced stability and dermal delivery of 
hydroquinone using solidlipid nanoparticles. Colloids Surf B 
2015;136:1004–10. 
17. Barry BW. Mode of action of penetration enhancers in human 
skin. J Controlled Release 1987;6:85–97. 
18. Rathod BH, Rani SS, Kartheek N, Kumar A. UV 
spectrophotometric method development and validation for 
the quantitative estimation of indinavir sulphate in capsules. 
Int J Pharm Pharm Sci 2014;6:598-601. 
19. Yasmeen Z, Mamatha T, Farheen H. Dissolution method 
development and validation for a combination of ibuprofen and 
paracetamol tablets. Asian J Pharm Clin Res 2013;6:164-8. 
20. Khanchandani SS, Galgatte UC, Chaudhari PD. Development and 
validation of a UV-visible spectroscopic method for estimation 
of rizatriptan benzoate in bulk and tablet dosage form. Asian J 
Pharm Clin Res 2013;6:113-6. 
21. Moharana AK, Banerjee M, Panda S, Mudali JN. Development 
and validation of UV spectrophotometric method for the 
determination of mesalamine in bulk and tablet formulation. 
Int J Pharm Pharm Sci 2011;3:19-21. 
22. Nazemiyeh E, Eskandani M, Sheikhloie H, Nazemiyeh H. 
Formulation and physicochemical characterization of 
lycopene-loaded solid lipid nanoparticles. Adv Pharm Bull 
2016;6:235-41. 
23. Sisinthy SP, Duraipandi S, Rao NK, Rao MB. Determination and 
validation of HPLC with UV-detection of Itopride hydrochloride 
in human serum. Int J Pharm Pharm Sci 2015;7:246-9. 
24. Sheliya K, Shah K, Kapupara P. Development and validation of 
analytical method for simultaneous estimation of mometasone 
furoate, hydroquinone and tretinoin in the topical formulation 
by RP-HPLC. J Chem Pharm Res 2014;6:934-40. 
25. Kipngetich TE, Hillary M, Shadrack M. UV-Vis analysis and 
determination of hydroquinone in body lotions and creams 
sold in retail outlets in baraton, Kenya. Baraton 
Interdisciplinary Res J 2013;3:23-8. 
26. Beckett AH, Stenlake JB. Practical pharmaceutical chemistry. 4th 
ed. Part 2. New Delhi: CBS Publishers and distributors; 1997. 
27. Kumar BK, Thiruvengadarajan VS, Begum NT. Analytical 
method development and validation of lidocaine in ointment 
formulation by the UV-spectrophotometric method. Int J Pharm 
Pharm Sci 2012;4:610-4. 
28. Balasaheb BG, Balasaheb AK, Subhash TR, Jijabapu K, Sudhakar 
PS. Development and validation of a UV-spectrophotometric 
method for estimation of dolutegravirsodium in tablet dosage 
form. Malaysian J Anal Sci 2015;19:67-78. 
29. Joana G, Zelia B. Validation of two spectrophotometric methods 
for fluoxetine quantification. Int J Pharm Pharm Sci 2016;8:72-8. 
30. Jain PS, Chaudhari AJ, Patel SA, Patel ZN, Patel DT. Development 
and validation of the UV spectrophotometric method for 
determination of terbinafine hydrochloride in bulk and in the 
formulation. Pharm Methods 2011;2:89-95. 
31. Sharma K, Agarwal SS, Gupta M. Development and validation of 
a UV-spectrophotometric method for estimation of curcumin in 
bulk drug and pharmaceutical dosage forms. Int J Drug Dev Res 
2012;4:375-80. 
32. Ethiraj R, Thiruvengadam E, Sampath VS, Vahid A, Raj J. 
Development and validation of stability indicating a 
spectroscopic method for content analysis of ceftriaxone 
sodium in pharmaceuticals. Int Scholarly Res Not 2014. 
http://dx.doi.org/10.1155/2014/278173 
33. ICH, Q2 (R1) Validation of analytical procedure, text and 
methodology. International Conference on Harmonization; 
2016. 
How to cite this article 
• Sukhjinder Kaur, Taranjit Kaur, Gurdeep Kaur, Shivani Verma. 
Development and validation of a UV-spectrophotometric method 
for estimation of hydroquinone in bulk marketed cream and 
prepared NLC formulation. Int J Appl Pharm 2017;9(5):102-108. 
 
